TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT TYPE LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET TESTING TYPE COVERAGE GRID 30
2.11 VENDOR SHARE ANALYSIS 31
2.12 SECONDARY SOURCES 32
2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 35
4.1 PESTEL ANALYSIS 38
4.2 PORTER ANALYSIS 39
5 INDUSTRY INSIGHTS 40
6 REGULATORY FRAMEWORK 42
7 MARKET OVERVIEW 44
7.1 DRIVERS 46
7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS 46
7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI 46
7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 47
7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS 47
7.2 RESTRAINTS 48
7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR 48
7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 48
7.3 OPPORTUNITIES 49
7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION 49
7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI 49
7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE 50
7.4 CHALLENGES 51
7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT 51
7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS 51
8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT 52
8.1 OVERVIEW 53
8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 56
8.2.1 BY ENZYME 56
8.2.1.1 LIPASE 57
8.2.1.2 PROTEASE 57
8.2.1.3 AMYLASE 57
8.2.2 BY ROUTE OF ADMINISTRATION 57
8.2.2.1 ORAL 58
8.2.2.1.1 CAPSULES 58
8.2.2.1.2 TABLETS 58
8.2.2.1.3 POWDER 58
8.2.2.2 INTRAVENOUS 58
8.3 NUTRITIONAL MANAGEMENT 59
8.3.1 VITAMIN D 60
8.3.2 VITAMIN E 60
8.3.3 VITAMIN A 60
8.3.4 VITAMIN K 60
8.3.5 OTHERS 60
9 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS 61
9.1 OVERVIEW 62
9.2 PANCREATIC FUNCTION TEST 64
9.2.1 STOOL 65
9.2.1.1 FECAL ELASTASE TEST 66
9.2.1.2 FECAL FAT TEST 66
9.2.2 SECRETIN PANCREATIC FUNCTION TEST 66
9.2.3 BLOOD TESTS 66
9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST 66
9.2.5 FASTING PLASMA GLUCOSE TEST 66
9.3 IMAGING TEST 66
9.3.1 CT SCANNING 68
9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI) 68
9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY 68
9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS) 68
9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY 68
10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE 69
10.1 OVERVIEW 70
10.2 BRANDED 72
10.2.1 CREON 73
10.2.2 ZENPEP 74
10.2.3 PANCREAZE 74
10.2.4 NUTRIZYM 74
10.2.5 PANCREASE MT 74
10.2.6 PANCREX 74
10.2.7 COTAZYM 74
10.2.8 ULTERSA 74
10.2.9 VIOKACE 74
10.2.10 PERTZYE 74
10.2.11 OTHERS 75
10.3 GENERIC 75
11 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER 76
11.1 OVERVIEW 77
11.2 HOSPITALS 79
11.2.1 PRIVATE 80
11.2.2 PUBLIC 80
11.3 SPECIALTY CLINICS 80
11.4 DIAGNOSTIC CENTER 81
11.5 HOMECARE 82
11.6 RESEARCH AND ACADEMIC INSTITUTES 83
11.7 OTHERS 84
12 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 85
12.1 OVERVIEW 86
12.2 DIRECT TENDER 88
12.3 RETAIL PHARMACY 89
12.4 THIRD PARTY DISTRIBUTORS 90
12.5 OTHERS 91
13 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION 92
13.1 OVERVIEW 93
13.2 NORTH AMERICA 97
13.2.1 U.S. 101
13.2.2 CANADA 101
13.2.3 MEXICO 101
13.3 EUROPE 102
13.3.1 GERMANY 107
13.3.2 FRANCE 107
13.3.3 U.K. 107
13.3.4 ITALY 107
13.3.5 SPAIN 107
13.3.6 RUSSIA 107
13.3.7 TURKEY 107
13.3.8 BELGIUM 107
13.3.9 DENMARK 107
13.3.10 NETHERLANDS 108
13.3.11 SWITZERLAND 108
13.3.12 SWEDEN 108
13.3.13 POLAND 108
13.3.14 NORWAY 108
13.3.15 FINLAND 108
13.3.16 REST OF EUROPE 108
13.4 ASIA PACIFIC 109
13.4.1 JAPAN 113
13.4.2 CHINA 113
13.4.3 SOUTH KOREA 113
13.4.4 INDIA 113
13.4.5 AUSTRALIA 113
13.4.6 NEW ZEALAND 113
13.4.7 SINGAPORE 113
13.4.8 THAILAND 113
13.4.9 MALAYSIA 113
13.4.10 VIETNAM 114
13.4.11 TAIWAN 114
13.4.12 INDONESIA 114
13.4.13 PHILIPPINES 114
13.4.14 REST OF ASIA-PACIFIC 114
13.5 SOUTH AMERICA 115
13.5.1 BRAZIL 119
13.5.2 ARGENTINA 119
13.5.3 REST OF SOUTH AMERICA 119
13.6 MIDDLE EAST AND AFRICA 120
13.6.1 SOUTH AFRICA 124
13.6.2 SAUDI ARABIA 124
13.6.3 BAHRAIN 124
13.6.4 U.A.E. 124
13.6.5 KUWAIT 124
13.6.6 OMAN 124
13.6.7 QATAR 124
13.6.8 EGYPT 124
13.6.9 ISRAEL 124
13.6.10 REST OF MIDDLE EAST AND AFRICA 125
14 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE 126
14.1 COMPANY SHARE ANALYSIS: GLOBAL 126
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 127
14.3 COMPANY SHARE ANALYSIS: EUROPE 128
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 129
15 SWOT ANALYSIS 130
16 COMPANY PROFILE 131
16.1 ABBVIE INC. 131
16.1.1 COMPANY SNAPSHOT 131
16.1.2 REVENUE ANALYSIS 131
16.1.3 COMPANY SHARE ANALYSIS 132
16.1.4 PRODUCT PORTFOLIO 132
16.1.5 RECENT DEVELOPMENT 132
16.2 ABBOTT 133
16.2.1 COMPANY SNAPSHOT 133
16.2.2 REVENUE ANALYSIS 133
16.2.3 COMPANY SHARE ANALYSIS 134
16.2.4 PRODUCT PORTFOLIO 134
16.2.5 RECENT DEVELOPMENT 134
16.3 NESTLE 135
16.3.1 COMPANY SNAPSHOT 135
16.3.2 REVENUE ANALYSIS 135
16.3.3 COMPANY SHARE ANALYSIS 136
16.3.4 PRODUCT PORTFOLIO 136
16.3.5 RECENT DEVELOPMENTS 136
16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022) 137
16.4.1 COMPANY SNAPSHOT 137
16.4.2 REVENUE ANALYSIS 137
16.4.3 COMPANY SHARE ANALYSIS 138
16.4.4 PRODUCT PORTFOLIO 138
16.4.5 RECENT DEVELOPMENT 138
16.5 JANSSEN GLOBAL SERVICES, LLC 139
16.5.1 COMPANY SNAPSHOT 139
16.5.2 REVENUE ANALYSIS 139
16.5.3 COMPANY SHARE ANALYSIS 140
16.5.4 PRODUCT PORTFOLIO 140
16.5.5 RECENT DEVELOPMENT 140
16.6 ALCRESTA THERAPEUTICS, INC. 141
16.6.1 COMPANY SNAPSHOT 141
16.6.2 COMPANY SHARE ANALYSIS 141
16.6.3 PRODUCT PORTFOLIO 142
16.6.4 RECENT DEVELOPMENT 142
16.7 BIOSERV DIAGNOSTICS GMBH 143
16.7.1 COMPANY SNAPSHOT 143
16.7.2 PRODUCT PORTFOLIO 143
16.7.3 RECENT DEVELOPMENT 143
16.8 CILIAN AG 144
16.8.1 COMPANY SNAPSHOT 144
16.8.2 PRODUCT PORTFOLIO 144
16.8.3 RECENT DEVELOPMENT 144
16.9 CHIRHOCLIN 145
16.9.1 COMPANY SNAPSHOT 145
16.9.2 COMPANY SHARE ANALYSIS 145
16.9.3 PRODUCT PORTFOLIO 146
16.9.4 RECENT DEVELOPMENT 146
16.10 DIGESTIVE CARE, INC. 147
16.10.1 COMPANY SNAPSHOT 147
16.10.2 PRODUCT PORTFOLIO 147
16.10.3 RECENT DEVELOPMENT 147
16.11 EAGLEBIO 148
16.11.1 COMPANY SNAPSHOT 148
16.11.2 PRODUCT PORTFOLIO 148
16.11.3 RECENT DEVELOPMENT 148
16.12 METAGENICS LLC 149
16.12.1 COMPANY SNAPSHOT 149
16.12.2 PRODUCT PORTFOLIO 149
16.12.3 RECENT DEVELOPMENT 149
16.13 NORDMARK 150
16.13.1 COMPANY SNAPSHOT 150
16.13.2 COMPANY SHARE ANALYSIS 150
16.13.3 PRODUCT PORTFOLIO 151
16.13.4 RECENT DEVELOPMENT 151
16.14 ORGANON GROUP OF COMPANIES. 152
16.14.1 COMPANY SNAPSHOT 152
16.14.2 REVENUE ANALYSIS 152
16.14.3 PRODUCT PORTFOLIO 153
16.14.4 RECENT DEVELOPMENT 153
16.15 SCHEBO BIOTECH AG 154
16.15.1 COMPANY SNAPSHOT 154
16.15.2 PRODUCT PORTFOLIO 154
16.15.3 RECENT DEVELOPMENT 154
16.16 VIVUS LLC 155
16.16.1 COMPANY SNAPSHOT 155
16.16.2 COMPANY SHARE ANALYSIS 155
16.16.3 PRODUCT PORTFOLIO 156
16.16.4 RECENT DEVELOPMENT 156
17 QUESTIONNAIRE 157
18 RELATED REPORTS 160

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.